Article Text
Commentary
Lessons from type I interferons in ulcerative colitis
Statistics from Altmetric.com
Footnotes
Linked articles 226860.
Funding The authors' laboratories are supported by NIH RO1 grants DK44319, DK51362, DK53056 and DK08819 (RSB), T32 DK07533-21A1 (RSB) and P30 DK034854 (Harvard Digestive Diseases Center), European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement no. 260961 (AK), the Austrian Science Fund and Ministry of Science P21530 (AK) and START Y446 (AK), and the National Institute for Health Research Cambridge Biomedical Research Centre (AK). RSB is listed as co-inventor on a patent involving IL-13 targeting for the treatment of UC.
Competing interests None.
Provenance and peer review Commissioned; not externally peer reviewed.